B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Neutral 55.4%

Neg 0% Neu 55.4% Pos 0%

B of A Securities analyst Travis Steed maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $35 to $25.